Navigation Links
Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
Date:3/27/2013

SAN DIEGO, March 27, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist, in development by AbbVie for the treatment of uterine fibroids and endometriosis. Neurocrine and AbbVie entered into a collaboration and license agreement for elagolix during 2010.

"Based on the positive data from the uterine fibroids Phase IIa trial, AbbVie has progressed elagolix into Phase IIb for uterine fibroids," said Kevin C. Gorman , President and Chief Executive Officer of Neurocrine Biosciences. "We are pleased with this advancement, as well as the ongoing Phase III program in endometriosis, and look forward to the continued development of elagolix in these two disease states which both have high unmet medical needs."

The Phase IIb uterine fibroids study is a randomized, parallel, double-blind, placebo-controlled clinical trial evaluating elagolix in women with heavy uterine bleeding associated with uterine fibroids. This study will evaluate 280 subjects over a six-month placebo-controlled dosing period. The primary efficacy endpoint of the study is an assessment of the change in menstrual blood loss utilizing the alkaline hematin method comparing baseline to month six. Additional secondary efficacy endpoints will be evaluated including assessing the change in fibroid volume and hemoglobin. Bone mineral density will be assessed via DXA scan at baseline, the conclusion of dosing, and six months post-dosing.

About Uterine Fibroids

Uterine fibroids are benign hormonally responsive tumors that form in the wall of the utervus. They are the most common type of abnormal growth found in a woman's pelvis and are mos
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
2. Neurocrine Biosciences Reports First Quarter 2012 Results
3. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
5. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
7. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
8. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
11. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... and TORONTO , Aug. 27, 2015 ... today announced the issuance of a white paper on ... insulin spray product.  The white paper was presented to ... stockholders by Dr. James H. Anderson, Jr. , ... may be viewed online on the Generex website. ...
(Date:8/27/2015)... 2015 Major pharmaceutical and medical device companies and ... in Philadelphia on Oct. 20, discussing ... Hagy of HB Litigation Conferences has announced. ... at http://litigationconferences.com/?p=31886 The program is co-chaired ... Mahoney and Michelle Hart Yeary of Dechert LLP. ...
(Date:8/27/2015)... Aug. 27, 2015  Mytrus, a technology and services company revolutionizing ... electronic informed consent has received approval for use by ... It is the first time e-Consent technology will be ... . Mytrus was also the first ... clinical trial by the U.S. Food and Drug Administration ...
Breaking Medicine Technology:Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7
... Services is pleased to announce the exciting addition of ... the new Manager of Minerals.  Dr. Al-Ammar brings with ... has over fourteen years of experience with ICP-MS and ... United States and Europe.  Additionally, Dr. Al-Ammar has seven ...
... 15, 2011 PPTA opposes New Jersey Assembly Bill 2003 ... 13 that imposes a new tax on therapies used to ... The Bleeding Disorders Treatment Fund by taxing the manufacturers of ... rebate. PPTA opposes any policy that would impose a tax ...
Cached Medicine Technology:Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing 2PPTA Opposes Tax on Blood Clotting Factor 2
(Date:8/27/2015)... , ... August 27, 2015 , ... ... Summit , scheduled for October 27-29, 2015 in San Jose, CA. The ... will primarily focus on the void that exists where battery development and energy ...
(Date:8/27/2015)... Reading, PA (PRWEB) , ... August 27, 2015 , ... ... Therapy programs, Alvernia University now offers a third doctoral program at its main campus ... is a terminal degree program designed to prepare advanced practice nurses for the ...
(Date:8/27/2015)... ... August 27, 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue ... of 2016. The new facility will be located at US Highway 19 North and Highlands ... on August 18, and work on the project is slated to begin in September 2015. ...
(Date:8/27/2015)... ... August 27, 2015 , ... NetDimensions is once again named ... the platforms required not only to effectively deliver, curate and administer great programs, but ... Inc. , For six consecutive years, NetDimensions has maintained its position on this ...
(Date:8/27/2015)... ... 27, 2015 , ... Z-Medica®, LLC, a leading developer and ... website http://www.Z-Medica.com , to further support the company’s corporate positioning. , The ... , “We launched a branded website last year to show our customers ...
Breaking Medicine News(10 mins):Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:Z-Medica® Launches New Corporate Website 2
... river is in the news again, for all the wrong ... York state are warning boaters and others who use the ... million gallons of raw sewage that reached the river after ... health concern would be for anyone coming in contact with ...
... alarm for parents about a common myth: that children dont ... so-called brain attacks each year, and half of them end ... ,Strokes in children may occur even more ... sadly, strokes in children are sometimes not recognized and treated, ...
... a one-year-old child having his foot amputated has moved ... an explanation. ,In January, a fractured leg brought ... his limb was plastered below the waist. However, the skin ... necessitating its surgical separation on March 5. ,A ...
... boys affected by Duchenne muscular dystrophy. A new study has found ... their own for a longer period of time and reduce their ... in 3,500 boys. Symptoms start in early childhood and rapidly progress ... and 11. There is no cure for the disorder. ...
... Former US president Bill Clinton has once again lent a ... fallout between the Brazil government and drug giant Merck ... diffuse the situation. Clinching a deal with two Indian pharmaceutical ... the companies to provide second-line AVR drugs and a next ...
... prescribed a drug that reduces their estrogen levels. But ... is widespread concern about how the estrogen-reducing drugs - ... ,A study at Washington University School of Medicine in ... aromatase inhibitors, and researchers are calling for interested women ...
Cached Medicine News:Health News:Sewage Flows into Hudson River in a Torrent 2Health News:Sewage Flows into Hudson River in a Torrent 3Health News:Childhood Strokes Linked to Whiplash, Other Traumatic Injury 2Health News:Court Seeks Explanation from Hospital for Childs Amputation 2Health News:Daily Steroids Helpful for Boys Down With Muscular Dystrophy 2Health News:Clinton Foundation Eases Over-Pricing Of AIDS Drugs Once More 2Health News:Study to Investigate Gene's Effect on Bone Loss in Breast Cancer Patients 2
Barraquer needle holder, curved, delicate....
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Medicine Products: